| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1674 | |
| Phytochemical name or plant extracts | Parmotrema reticulatum extract | |
| PMID | 24358166 | |
| Literature evidence | It can be hypothesised from the current study that the antioxidant and anticancer potential of the PRME may reside in the phytoconstitutents present in it and therefore, PRME may be used as a possible source of natural antioxidant that may be developed to an anticancer agent. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic extract | |
| Source of phytochemicals or plant Extracts | Parmotrema reticulatum | |
| Geographical availability | NA | |
| Plant parts | Lichen | |
| Other cancers | Breast cancer | |
| Target gene or protein | Bax, Bcl-2 , Caspase | |
| Gene or Protein evidence | These results suggest that PRME induced apoptosis through the regulation of Bax/Bcl-2 ratio and the activation of caspases. | |
| Target pathways | NA | |
| IC50 | 130.03±3.11 µg/ml against MCF-7 | |
| Potency | PRME may be used as a possible source of natural antioxidant that may be developed to an anticancer agent. | |
| Cell line/ mice model | MCF-7, A549, WI-38 | |
| Additional information | Further flow cytometric study showed that PRME halted the MCF-7 cells in S and G2/M phases and induces apoptosis in dose as well as time dependent manner. Cell cycle arrest was associated with downregulation of cyclin B1, Cdk-2 and Cdc25C as well as slight decrease in the expression of Cdk-1 and cyclin A1 with subsequent upregulation of p53 and p21. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |